Navigation Links
Researchers explore the antidepressant effects of ketamine
Date:2/21/2008

Philadelphia, PA, February 21, 2008 Drug treatments for depression can take many weeks for the beneficial effects to emerge. The excruciating and disabling nature of depression highlights the urgency of developing treatments that act more rapidly. Ketamine, a drug used in general medicine as an anesthetic, has recently been shown to produce improvements in depressed patients within hours of administration. A new study being published in the February 15th issue of Biological Psychiatry provides some new insight into the mechanisms by which ketamine exerts its effects.

Ketamine is classified as an N-methyl d-aspartate (NMDA) glutamate receptor antagonist. Maeng and colleagues now provide new evidence that these antidepressant effects of NMDA receptor antagonists are mediated by their ability to increase the stimulation of -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptors. In other words, their findings indicate that the antidepressant-like effects of drugs like ketamine are dependent on AMPA receptor stimulation. This suggests that drugs that enhance AMPA receptor function might have rapid antidepressant properties.

Dr. Husseini Manji, corresponding author on this paper and a Deputy Editor of Biological Psychiatry, explains that by aiming new medications at more direct molecular targets, such as NMDA or AMPA, we may be able to bypass some of the steps through which current antidepressants indirectly exert their effects a roundabout route that accounts for the long time it takes for patients to begin feeling better with the conventional medications. He adds, Todays antidepressant medications eventually end up doing the same thing, but they go about it the long way around, with a lot of biochemical steps that take time. Now weve shown what the key targets are and that we can get at them rapidly.

This study is especially important because even though this important antidepressant effect has been found in ketamine, its use also has significant drawbacks. According to John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, the only NMDA receptor antagonist found to be effective so far, ketamine, produces transient changes in perception and impairments in cognition. It is also in the same class of drugs as PCP (phencyclidine) and can cause hallucinations, among other side effects. Dr. Krystal notes that it is possible that drugs that directly enhance the activity of AMPA glutamate receptors, the AMPAkines, would have antidepressant effects similar to ketamine, without the unwanted side effects. Exploring the antidepressant effects of the AMPAkines will now be an important target for researchers.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Researchers Make Stem Cells That Secrete Insulin
2. U of M researchers determine structure of protein that mutates DNA of the AIDS virus HIV-1
3. Researchers create first chikungunya animal model
4. Researchers aim to prevent global prematurity and stillbirths
5. Researchers Aim to Prevent Global Prematurity and Stillbirths
6. UH researchers study Hispanic childrens activities, views on places to play
7. Researchers discover new way to reverse poor circulation and heal wounds
8. Bacterial toxin closes gate on immune response, Penn researchers discover
9. UD researchers discover technique for repairing gene defect that causes spinal muscular atrophy
10. Veterinary researchers study poultry virus as human cancer treatment
11. UD researchers discover promising technique for repairing gene that causes spinal muscular atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , ... April 28, 2016 , ... University of New ... to the role of vice president of Student Engagement. In addition to his ... athletics and student life areas. , “In the space of just one year ...
(Date:4/28/2016)... ... , ... Cosmetic Town, an online plastic surgery community, announces the relaunch of ... revamped and upgraded to allow even more interaction between doctors and patients as well ... to the senior editor of Cosmetic Town, “We are excited that our forum ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, contamination ... mortality. This is particularly true in underdeveloped parts of Africa where clean sources of ... England’s campus in Tangier, Morocco, will examine this global health issue and consider how ...
(Date:4/28/2016)... ... April 28, 2016 , ... Altima ... announces today the availability of its latest software release, NetZoomDC 14.5. , ... and optimization, providing new analytical capabilities that assess complex capacity factors and ...
(Date:4/28/2016)... ... 2016 , ... Amada Senior Care, premier provider of non-medical in-home care and ... San Antonio West location. Prior to entering the senior care industry, Amada franchise partner ... Amada San Antonio West will take place on Friday, April 29th. , ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... April 28, 2016 Treato ... on healthcare, announced today that it has been named ... Cool Vendor in Life Sciences, 2016, Stephen ...  The report focuses on life-science- oriented analytics, algorithms and ... patients and doctors, confirm medication ingestion, and analyze unstructured ...
(Date:4/28/2016)... -- Dr. Vivek Ahuja , ... Ste phen Schmidt Join ... cloud-based software solutions for life sciences, today announced key new leaders ... of insight to a growing business.  This will bolster the company,s ... Phillips joined ArisGlobal in the position of Vice President - ...
Breaking Medicine Technology: